INFLATED LEVELS OF SCFA, BIFIDOBACTERIA AND LACTOBACILLUS IMPROVES THE STATUS OF PRE HYPERTENSION AND TYPE 2 DIABETES MELLITUS IN SUBJECTS RESIDING IN NORTH EAST INDIAâ€“A RANDOMIZED CONTROL TRIAL WITH SYNBIOTIC SUPPLEMENTATION
Objective: The study was undertaken to determine the effect of synbiotic supplementation on glycemia, gut health and Short chain fatty acid (SCFA) levels in pre hypertensive type 2 diabetic adults.
Methods: 60 pre hypertensive adults with type II NIDDM aged 35-55yrs were purposively selected from Sun Valley Hospital, form north east state of India, and based on the informed consent given by the subjects they were randomly divided into Control (N=10) and Experimental groups (N=25). The experimental group was supplemented with 1 gm of freeze dried synbiotic product (2 species of Lactobacillus, Bifidobacterium each, one species of Streptococcus, one species of yeast along with 300 mg Fructo oligosaccharide) daily to be taken along with meals, for 45 days. Glycemic parameters were determined using an enzymatic method. DNA was isolated from the stool samples and was quantified for determination of LAB, Bifidobacteria and Enteric pathogens using PCR techniques. SCFA was determined using Gas Chromatography Mass Spectrophotometer (GCMS).
Results: Intervention with synbiotic supplementation resulted in a significant reduction in FBS, PP2BS, HbA1c, by 3.3%, 6.7%, 14%, respectively along with a significant increment in butyrate (547.4%) and propionate (310%) levels. Gut health of the subjects improved significantly as indicated by increased colonization of Bifidobacteria (131.6%) and LAB (32.6%) and a significant reduction in enteric pathogens (44.6%).
Conclusion: Daily intake of 1 g freeze dried synbiotic product is an attractive therapy to improve glycemia, gut health which may be implicated by increased production of SCFA.
2. Moroti C, Souza Magri LF, De Rezende Costa M, CU Cavallini D, Sivieri K. Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. Lipids Health Dis 2012;11: doi: 10.1186/1476-511X-11-29. [Article in Press].
3. Sheth M, Parnami S. Improvement in lipid regulation and intestinal microflora as a result of probiotic curd intake in institutionalized elderly. Indian J Geronat 2011;27:541-62.
4. Sheth M, Assudani A. Newer stratergy to combat obesity amongst the bank employees of Urban Vadodara-Insights into its mechanism. World J Pharm Pharm Sci 2015;4:658-72.
5. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007;56:1761â€“72.
6. Alles MS, De Roos NM, Bakx JC. Consumption of FOS does not affect blood glucose and serum lipid concentrations in patients with type 2 diabetes. Am J Clin Nutr 1999;69:64-9.
7. Macfarlane S, Macfarlane GT. Regulation of short-chain fatty acid production. Proc Nutr Soc 2003;62:67-72.
8. Flint HJ, Louis P. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett 2009;294:1â€“8.
9. Demigne C, Remesy C. Morland, Short-chain fatty acids, Colonic microbiota, Nutrition and health; 1999.
10. Xiao J, Kondo S, Takahashi N, Miyaki K, Oshida K, Hiramatsu A. Effects of milk products fermented by Bifidobacterium longum on blood lipids in rats and healthy adult male volunteers. J Dairy Sci 2003;86:2452â€“61.
11. Samuel BS, Shaito A, Motoike T, Rey FE, Backhed F, Manchester JK, et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc Natl Acad Sci USA 2008;105(43):16767-72.
12. Mahendra A, Sheth M. Gut microflora affects Glycemia response of type 2 diabetic adults: A cross-sectional study. Int J Basic Appl Med Sci 2015;2(3):2277-103.
13. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003;361(9356):512-9.
14. Louis P. Restricted distribution of the butyrate kinase pathway among butyrate-producing bacteria from the human colon. J Bacteriol 2004;186:2099â€“106.
15. Van Immerseel F, Ducatelle R, De Vos M, Boon N, Van De Wiele T, Verbeke K, et al. Butyric acid-producing anaerobic bacteria as a novel probiotic treatment approach for inflammatory bowel disease. J Med Microbiol 2010;59:141â€“3.
16. Fuller R. Probiotic in man and animals. J Appl Bacteriol 1989;66:365-78.
17. Servin AL. Antagonist activities of Lactobacillus and Bifidobacteria against microbiol pathogen. FEMS Microbiol Rev 2004;28:405-40.
18. Hashiba H FS, Hirota T, Forstner JF. Inhibition of the binding of enterotoxicogenuc E. Coli Pb176 to human intestinal epithelial cell line HCT-8 by an extracellular protein fraction containing BIF of Bifidobacterium longum SBT 2928:suggestive evidence of blocking of the binding receptor gangliotetrasylceramide on the cell surface. Int J Food Microbiol 2001;67:97-106.
19. Gopal PK, Prasad J, Smart J, Gill HS. In vitro adherence properties of Lactobacillus rhamnosus DR20 and Bifidobacteria lactis DR10 strains and their antagonist activity against on enterotoxigenic E. Coli. Int J Food Microbiol 2001;67:207-16.